Adaptive behavior and psychiatric comorbidities in KCNB1 encephalopathy.


Journal

Epilepsy & behavior : E&B
ISSN: 1525-5069
Titre abrégé: Epilepsy Behav
Pays: United States
ID NLM: 100892858

Informations de publication

Date de publication:
01 2022
Historique:
received: 05 09 2021
revised: 23 11 2021
accepted: 25 11 2021
pubmed: 17 12 2021
medline: 19 3 2022
entrez: 16 12 2021
Statut: ppublish

Résumé

KCNB1 encephalopathy encompasses a broad phenotypic spectrum associating intellectual disability, behavioral disturbances, and epilepsies of various severity. Using standardized parental questionnaires, we aimed to capture the heterogeneity of the adaptive and behavioral features in a series of patients with KCNB1 pathogenic variants. We included 25 patients with a KCNB1 encephalopathy, aged from 3.2 to 34.1 years (median = 10 years). Adaptive functioning was assessed in all patients using the French version of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) questionnaire. We screened global behavior with the Childhood Behavioral Check-List (CBCL, Achenbach) and autism spectrum disorder (ASD) with the Social Communication Questionnaire (SCQ). We used a cluster analysis to identify subgroups of adaptive profiles. VABS-II questionnaire showed pathological adaptive behavior in all participants with a severity of adaptive deficiency ranging from mild in 8/20 to severe in 7/20. Eight out of 16 were at risk of Attention Problems at the CBCL and 13/18 were at risk of autism spectrum disorder (ASD). The adaptive behavior composite score significantly decreased with age (Spearman's Rho=-0.72, p<0.001) but not the equivalent ages, suggesting stagnation and slowing but no regression over time. The clustering analysis identified two subgroups of patients, one showing more severe adaptive behavior. The severity of the epilepsy phenotype predicted the severity of the behavioral profile with a sensitivity of 70% and a specificity of 90.9%. This study confirms the deleterious consequences of early-onset epilepsy in addition to the impact of the gene dysfunction in patients with KCNB1 encephalopathy. ASD and attention disorders are frequent. Parental questionnaires should be considered as useful tools for early screening and care adaptation.

Identifiants

pubmed: 34915430
pii: S1525-5050(21)00732-0
doi: 10.1016/j.yebeh.2021.108471
pii:
doi:

Substances chimiques

KCNB1 protein, human 0
Shab Potassium Channels 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108471

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Claire Bar (C)

APHP, Reference Centre for Rare Epilepsies, Department of Pediatric Neurology, Hôpital Necker-Enfants Malades, member of ERN EPICARE, Université de Paris, Paris, France; Laboratory of Translational Research for Neurological Disorders, INSERM UMR 1163, Imagine Institute, Université de Paris, Paris, France.

Delphine Breuillard (D)

APHP, Reference Centre for Rare Epilepsies, Department of Pediatric Neurology, Hôpital Necker-Enfants Malades, member of ERN EPICARE, Université de Paris, Paris, France; Laboratory of Translational Research for Neurological Disorders, INSERM UMR 1163, Imagine Institute, Université de Paris, Paris, France.

Mathieu Kuchenbuch (M)

APHP, Reference Centre for Rare Epilepsies, Department of Pediatric Neurology, Hôpital Necker-Enfants Malades, member of ERN EPICARE, Université de Paris, Paris, France; Laboratory of Translational Research for Neurological Disorders, INSERM UMR 1163, Imagine Institute, Université de Paris, Paris, France.

Mélanie Jennesson (M)

Department of Pediatrics, American Memorial Hospital, Reims, France.

Gwenaël Le Guyader (G)

Department of Genetics, CHU de Poitiers, BP 577, 86021 Poitiers Cedex, France; EA3808 - NEUVACOD Unité neurovasculaire et troubles cognitifs, Université de Poitiers, Pôle Biologie Santé, France.

Hervé Isnard (H)

Pediatric Neurologist, Medical Office 28 rue de la république, Lyon 69002, France.

Anne Rolland (A)

Department of Pediatrics, CHU de NANTES, Nantes, France.

Diane Doummar (D)

Department of Pediatric Neurology, AP-HP, Hôpital Armand Trousseau, Sorbonne Université, Paris, France.

Joel Fluss (J)

Pediatric Neurology Unit, Geneva Children's Hospital, 6 rue Willy-Donzé, 1211 Genève 4, Switzerland.

Alexandra Afenjar (A)

Sorbonne Universités, Centre de Référence Malformations et maladies congénitales du cervelet et déficiences intellectuelles de causes rares, département de génétique et embryologie médicale, Hôpital Trousseau, AP-HP, Paris, France.

Patrick Berquin (P)

Department of Pediatric Neurology, CHU Amiens-Picardie, Université de Picardie Jules Verne, Amiens France Pediatric Neurology Unit, France.

Anne De Saint Martin (A)

Department of Pediatric Neurology, Strasbourg University Hospital, Strasbourg, Hôpital de Hautepierre, Strasbourg, France.

Sophie Dupont (S)

Epileptology Unit and Rehabilitation Unit AP-HP, GH Pitie-Salpêtrière-Charles Foix, F-75013 Paris, France; Sorbonne University, UPMC Univ. Paris 06, F-75005 Paris, France.

Alice Goldenberg (A)

Centre de Référence Anomalies du Développement et Syndromes Malformatifs, CHU Rouen, Rouen, France.

Damien Lederer (D)

Human Genetic Centre, IPG, Gosselies, Belgium.

Gaétan Lesca (G)

Department of Genetics, Hospices Civils de Lyon, 69002 Lyon, France; Institut NeuroMyoGène, CNRS UMR 5310 - INSERM U1217, Université de Lyon, Université Claude Bernard Lyon 1, France.

Hélène Maurey (H)

Department of Pediatric Neurology, AP-HP, Hôpital Universitaire Bicêtre, Kremlin Bicêtre, France.

Pierre Meyer (P)

Department of Pediatric Neurology, CHU Montpellier, Montpellier, France; PhyMedExp, U1046 INSERM, UMR9214 CNRS, Université de Montpellier, Montpellier, France.

Cyril Mignot (C)

INSERM, U 1127, CNRS UMR 7225, Sorbonne Université, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France; APHP, Sorbonne Université, Groupe Hospitalier Pitié-Salpêtrière, Department of Genetics, Centre de Reference Déficience Intellectuelle de Causes Rares.

Anca Nica (A)

Neurology Department, Center for Clinical Research (CIC 1414), Rennes University Hospital, France; Laboratory Of Signal Processing (LTSI), UMR 1099 INSERM, Rennes F-35000, France.

Sylvie Odent (S)

Service de Génétique clinique, Reference Ccentre for Rare Developmental Abnormalities CLAD-Ouest, member of ERN ITHACA, CHU Rennes, France; CNRS UMR 6290 Institut de Génétique et Développement de Rennes IGDR, Univ Rennes, Rennes, France.

Alice Poisson (A)

GénoPsy, Reference Center for Diagnosis and Management of Genetic Psychiatric Disorders, Centre Hospitalier le Vinatier and EDR-Psy Team (Centre National de la Recherche Scientifique & Lyon 1 Claude Bernard University), France.

Emmanuel Scalais (E)

Pediatric Neurology Unit, Centre Hospitalier de Luxembourg, Luxembourg.

Tayeb Sekhara (T)

Department of Pediatric Neurology, C.H.I.R.E.C, Brussels, Belgium.

Pascal Vrielynck (P)

William Lennox Neurological Hospital, Reference Center for Refractory Epilepsy UCLouvain, Ottignies, Belgium.

Giulia Barcia (G)

Laboratory of Translational Research for Neurological Disorders, INSERM UMR 1163, Imagine Institute, Université de Paris, Paris, France; APHP, Department of Clinical Genetics, Necker-Enfants Malades Hospital, Paris, France.

Rima Nabbout (R)

APHP, Reference Centre for Rare Epilepsies, Department of Pediatric Neurology, Hôpital Necker-Enfants Malades, member of ERN EPICARE, Université de Paris, Paris, France; Laboratory of Translational Research for Neurological Disorders, INSERM UMR 1163, Imagine Institute, Université de Paris, Paris, France. Electronic address: rima.nabbout@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH